<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03185702</url>
  </required_header>
  <id_info>
    <org_study_id>HSC-MS-15-0120</org_study_id>
    <nct_id>NCT03185702</nct_id>
  </id_info>
  <brief_title>UTHealth Turner Syndrome Research Registry</brief_title>
  <official_title>UTHealth Turner Syndrome Research Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Heart Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Texas Health Science Center, Houston</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators will conduct genetic comparisons between Turner Syndrome (TS) patients with&#xD;
      and without Bicuspid Aortic Valve (BAV) to identify causative agents of BAV in people with&#xD;
      TS.&#xD;
&#xD;
      The investigators will correlate the patterns and prevalence of structural heart defects in&#xD;
      TS women with emerging molecular data to identify patients who are at high risk for&#xD;
      cardiovascular complications&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Turner syndrome (TS) is a common chromosomal disorder that affects approximately 1 in 2500&#xD;
      live female births. Complete or partial monosomy of one of the X chromosomes in a female is&#xD;
      associated with various congenital heart defects (CHDs), which include aortic dilatation,&#xD;
      coarctation of aorta and BAV. Congenital cardiovascular defects related to CHD are the&#xD;
      leading cause of death in women with TS. The Turner Syndrome Network Registry (TRN Registry)&#xD;
      and genetic sample repository can address gaps in knowledge of CHD in TS by facilitating the&#xD;
      recognition of demographic and genetic patterns. TRN Registry-based research can improve&#xD;
      surveillance of TS patients who are at risk for CHD and provide valuable insight into genetic&#xD;
      components of CHD.&#xD;
&#xD;
      The investigators will recruit TS patients into the TRN Registry and obtain blood and/or&#xD;
      saliva samples after informed consent. The genetic diagnosis of TS will be confirmed using&#xD;
      chromosomal microarrays. The array data will be also be used to identify genomic copy number&#xD;
      variants, and rare variants in protein coding genes will be determined by exome sequencing.&#xD;
      The investigators will derive induced pluripotent stem cells from some participants to&#xD;
      determine why CHD is so prevalent in TS. CHD risk genes will be identified in comparisons&#xD;
      between TS cases with and without congenital heart defects. To facilitate these comparisons,&#xD;
      the investigators will abstract the demographic and medical data of registry participants&#xD;
      from questionnaires and medical records. Imaging will be used to confirm the diagnosis of CHD&#xD;
      and to determine the prevalence and severity of additional cardiovascular defects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 28, 2015</start_date>
  <completion_date type="Anticipated">January 1, 2030</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2025</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>10 Years</target_duration>
  <primary_outcome>
    <measure>Bicuspid aortic valve and thoracic aortic aneurysm</measure>
    <time_frame>10 years</time_frame>
    <description>Imaging data</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life</measure>
    <time_frame>10 years</time_frame>
    <description>Access to care and guideline-recommended care</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Turner Syndrome</condition>
  <arm_group>
    <arm_group_label>Patients with Turner Syndrome</arm_group_label>
    <description>Chromosomal diagnosis and typical features</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Unaffected controls</arm_group_label>
    <description>Normal females and unaffected family members</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Research genetic tests</intervention_name>
    <description>DNA and tissue-based tests: karyotype, copy number variants, genome-wide association studies and induced pluripotent stem cells</description>
    <arm_group_label>Patients with Turner Syndrome</arm_group_label>
    <arm_group_label>Unaffected controls</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Saliva, blood, and tissue samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The study population consists of females diagnosed with Turner Syndrome. This diagnosis can&#xD;
        be based on physical symptoms (e.g. short stature, developmental delay, pubertal delay,&#xD;
        etc.) or karyotype (e.g. 45X/46XX mosaic, 45X, etc.).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of Turner Syndrome&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosis excluding Turner Syndrome&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Siddharth Prakash, MD, PhD</last_name>
    <phone>7135007003</phone>
    <email>Siddharth.K.Prakash@uth.tmc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Texas Health Science Center Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacqueline Jennings</last_name>
      <email>TSRegistry@uth.tmc.edu</email>
    </contact>
    <contact_backup>
      <phone>713-500-6704</phone>
    </contact_backup>
    <investigator>
      <last_name>Siddharth Prakash, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michelle Rivera-Davila, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>June 9, 2017</study_first_submitted>
  <study_first_submitted_qc>June 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 14, 2017</study_first_posted>
  <last_update_submitted>November 4, 2020</last_update_submitted>
  <last_update_submitted_qc>November 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center, Houston</investigator_affiliation>
    <investigator_full_name>Siddharth Prakash</investigator_full_name>
    <investigator_title>Associate Professor, Internal Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Turner Syndrome</mesh_term>
    <mesh_term>Gonadal Dysgenesis</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified genetic and clinical IPD data will be shared with approved researchers with local IRB approval after authorization from the UTHouston study team. Aggregate data will be made available to the general research community through NIH databases.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

